One To Watch
Vincentage Pharma
Company Overview
A Chengdu-based biotech racing to become the first oral small-molecule GLP-1 receptor agonist approved in China, with Phase III data showing up to 12.4% weight loss at 52 weeks in obese and overweight adults. Vincentage Pharma has concentrated its pipeline on oral small-molecule therapeutics for cardiometabolic conditions — a deliberate contrast to the injectable GLP-1 drugs that currently dominate the obesity market globally. The company targets obesity, type 2 diabetes, hypertension, and MASH, all conditions carrying outsized prevalence in China and significant unmet need despite recent advances.
Headquarters and Global Presence
Vincentage is headquartered in Chengdu, Sichuan province, China. Its Greater China commercial and development rights cover mainland China, Hong Kong, Macau, and Taiwan, with worldwide ex-Greater China rights out-licensed to Corxel Pharmaceuticals, giving VCT220 a simultaneous development footprint in the US and China.
Founding and History
Vincentage was established in 2021, making it one of the newer entrants in the crowded GLP-1 space. Despite its young age, the company moved quickly to a Phase III trial in China and executed a significant out-licensing deal with Corxel Pharmaceuticals in November 2024. That transaction, which triggered Corxel's $287 million Series D1 raise, validated the asset at a level unusual for a company only three years old.
Therapy Areas and Focus
The company's entire pipeline is oriented around cardiometabolic disease — obesity, type 2 diabetes, hypertension, and MASH. China carries one of the world's largest burdens of obesity-related metabolic disease, with an estimated 250 million adults living with obesity or overweight, and injectable GLP-1 therapies remain logistically and economically inaccessible for much of the population. An oral, once-daily pill addresses both the adherence and access barriers that have limited penetration of existing agents. MASH is a longer-range ambition, but GLP-1 receptor agonism has demonstrated biological plausibility in that indication and represents a natural pipeline extension.
Technology Platforms and Modalities
Vincentage's platform is built around oral small-molecule GLP-1 receptor agonism — a mechanistic class that activates the same pathway as semaglutide and tirzepatide but through a chemically distinct, non-peptide mechanism that enables oral bioavailability without the formulation complexity of peptide-based tablets. Small-molecule GLP-1 agonists are generally more manufacturable and dose-flexible than peptide analogues, and avoid the absorption-window dependency that has complicated oral semaglutide. VCT220's once-daily dosing, confirmed effective at 120 mg and 160 mg in Phase III, suggests the molecule has a clean pharmacokinetic profile. The broader pipeline applies this small-molecule approach across the cardiometabolic spectrum.
Key Pipeline and Programs
VCT220 is Vincentage's lead asset — a once-daily oral small-molecule GLP-1 receptor agonist in Phase III development in China for weight management in obese or overweight adults. The pivotal trial reported top-line data on May 18, 2026: at 52 weeks, mean body weight reduction was -12.2% in the 120 mg group and -12.4% in the 160 mg group, against -1.3% for placebo. The company plans to submit a New Drug Application to China's NMPA for the weight management indication in the near term. Beyond obesity, Vincentage is exploring VCT220 in type 2 diabetes, hypertension, and other cardiometabolic diseases, meaning the asset could anchor multiple indications across the same receptor target. In the United States, VCT220 is being developed by Corxel Pharmaceuticals under the ex-Greater China license, where it is currently in Phase II — a parallel track that will generate geographically diverse clinical evidence for the molecule without Vincentage bearing the capital cost.
Recent Developments
On May 18, 2026, Vincentage announced positive top-line Phase III results for VCT220, the headline event that positions the company for an imminent NMPA NDA submission. The data place VCT220 in direct competition with Eli Lilly's oral GLP-1 candidate in China, a race to regulators with significant commercial stakes. The Corxel licensing deal in November 2024, which unlocked $287 million in US-side funding, remains the most consequential external validation the company has received to date.
Key Personnel
Ben Li, Ph.D., serves as Chief Executive Officer of Vincentage Pharma. Li led the company from its 2021 founding through Phase III completion and the Corxel out-licensing transaction, the two defining milestones in its short history. Further executive team details are not publicly disclosed.
Strategic Partnerships
In November 2024, Vincentage out-licensed worldwide ex-Greater China development and commercialization rights for VCT220 to Corxel Pharmaceuticals. The deal directly catalyzed Corxel's $287 million Series D1 financing round, underscoring external confidence in the asset's profile. Vincentage retains full rights in mainland China, Hong Kong, Macau, and Taiwan — the markets where VCT220's NMPA filing is most advanced.
FAQ Section
Vincentage retains all Greater China rights — mainland China, Hong Kong, Macau, and Taiwan — and is pursuing an NMPA NDA submission for VCT220 following positive Phase III data. Worldwide ex-Greater China rights sit with Corxel Pharmaceuticals, which is running a Phase II trial in the US backed by $287 million in Series D1 capital. The structure lets Vincentage pursue its highest-priority market without carrying the cost of a parallel US development program.
The GLP-1 receptor regulates satiety, insulin secretion, and gastric emptying — a pathway whose therapeutic importance has been confirmed by the commercial and clinical success of injectable semaglutide and tirzepatide. Small-molecule agonists activate the same receptor without requiring injection or the complex formulation of peptide-based oral tablets, potentially simplifying manufacturing, improving patient adherence, and lowering cost-of-goods at scale. For a market like China, where price sensitivity and distribution infrastructure are both clinical realities, the oral small-molecule route is not just a scientific choice but a commercial one.
Oral semaglutide (Rybelsus) is a GLP-1 peptide that requires a fasting-state absorption protocol and delivers weight loss of around 4-5% in its approved diabetes dose — a profile limited partly by the constraints of peptide oral delivery. VCT220 is a non-peptide small molecule, meaning it does not carry those absorption restrictions, and its Phase III data showed -12.2% to -12.4% weight reduction at 52 weeks in an obesity population, a magnitude broadly comparable to injectable GLP-1 therapies. Whether that efficacy translates in a Western population, and how the safety profile compares head-to-head, are questions Corxel's Phase II in the US will begin to answer.
The trial enrolled overweight or obese participants in China and ran for 52 weeks. Both active doses — 120 mg and 160 mg once daily — produced mean body weight reductions of -12.2% and -12.4% respectively, compared with -1.3% for placebo, a difference that was statistically significant. The magnitude sits in a clinically meaningful range and compares favorably with injectable agents, though as an unblinded top-line read, full efficacy and safety data will be required for regulatory assessment. Vincentage has signaled an NDA submission to China's NMPA as the near-term next step.
Obesity is the lead indication, but the company is actively exploring VCT220 in type 2 diabetes, hypertension, and MASH. All four conditions cluster mechanistically around GLP-1 receptor biology and metabolic dysfunction, making multi-indication development from a single asset scientifically plausible. MASH in particular has attracted significant industry attention following the first regulatory approvals in that space, and GLP-1 agonism has shown early biological activity — a longer-horizon opportunity Vincentage appears to be keeping open.
With Phase III complete and positive top-line results in hand as of May 2026, Vincentage is in the late-stage/pre-NDA position for its lead asset in China. An NMPA submission for weight management is the immediate next milestone. Simultaneously, Corxel is running VCT220 through Phase II in the US, so the global evidence base for the molecule will expand in parallel. Label expansion into type 2 diabetes, hypertension, and MASH would extend the asset's commercial runway substantially beyond the initial obesity approval.
The company is at an inflection point, with several variables that will shape its trajectory over the next 12-24 months:
Today's issue
| Headless Content Management with Blaze